Breast Cancer News
In this section, access cutting-edge news about newly diagnosed breast cancer including treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Women treated for breast cancer with radiation therapy are more likely to die from heart disease 20 years or more down the line than women who don't get radiation, according to a new study.
The PAL Trial, announced at the 2010 San Antonio Breast Cancer Symposium, showed that women whose lymph nodes are removed during breast cancer surgery may safely lift weights of 1 to 2 pounds without increasing their chances for developing lymphedema.
NEW YORK (Reuters Health) - A new radiation treatment for breast cancer is becoming increasingly popular despite lack of good evidence, at least among well-insured Medicare patients, U.S. researchers say,.
LOS ANGELES (Reuters) - Combining experimental antibody drug pertuzumab with Herceptin, an antibody first approved in 1998, and chemotherapy shrank tumors in nearly half of newly diagnosed breast cancer patients treated in a clinical trial.
NEW YORK (Reuters) - The Novartis osteoporosis drug Zometa failed to improve disease free survival of early breast cancer patients in a large clinical trial, but some benefit was observed in older patients who took the medicine, researchers said.
NEW YORK (Reuters Health) - Breast cancer survivors who struggle with hot flashes may find respite in an antidepressant, according to a new study that suggests the medication should be the go-to drug when the overheating is severe.
NEW YORK (Reuters Health) - Women who have breast reconstruction after cancer surgery tend to be happier with the cosmetic results of silicone implants than with saline-filled ones, a study published Monday suggests.
Taking aspirin regularly may decrease risk of death from breast cancer and risk of breast cancer metastasis for women who have had early-stage breast cancer, an analysis indicates.
Three weeks of higher dose radiation worked as well as the standard-dose, five-week schedule after a lumpectomy for invasive, lymph node-negative disease, study shows.
New standards for ER, PR tests in breast cancer have been released by American Society of Clinical Oncology and College of American Pathologists.